William Milligan

William Milligan

Bill Milligan has over 25 years of executive leadership experience in business and corporate development, product development, marketing, pricing, reimbursement, and financing in the biopharmaceutical industry across a range of companies, therapeutic technologies, indications and regions. Prior to his Cell & Gene Therapy experience as SVP Corporate & Business Development, Steminent, Biotherapeutics Inc. (Taiwan / USA) and VP Business Development, AventaCell Biomedical Co. (Taiwan / USA), Milligan served as Chief Business Officer for Migenix Inc. (TSE:MGI (Canada)), CEO / Director for Cytran Inc. (USA), and CEO / Director for Intellivax Inc. (USA) in the biotech sector. In Pharma, his roles included VP Sales Division, VP Biomedical Division and VP BD, Pricing, New Product Planning (Roche Canada), and Product Manager (Lilly Canada). Milligan has served as Chair; ISCT Strategies for Commercialization (SFC) Organizing Committee (2018, 2019), and is currently Co-Chair, ISCT Business Models and Investment Sub-committee. Detailed Bio: https://ca.linkedin.com/in/bill-milligan-051200b